A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab - intravenous solution|DRUG: Trastuzumab - subcutaneous solution|DRUG: Chemotherapy
Sponsor: Hoffmann-La Roche